The company faces a severe structural deficit, evidenced by a gross margin of -5.1% in 2026Q1 and an operating margin of -23.7% that reflects an inability to scale commercial operations.
| Sales/Revenue | 396.9K | 204.12K | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 820.02K | 617.45K | 773.9K | 891.25K | 654.57K | 28.7K | 11.04K | 10.59K |
| COGS % of Revenue | - | 302.49% | - | - | - | - | - | - |
| Gross Profit | -423.12K | -413.32K | -773.9K | -891.25K | -654.57K | -28.7K | -11.04K | -10.59K |
| Gross Margin % | -106.61% | -202.49% | - | - | - | - | - | - |
| Gross Profit Growth % | - | 46.59% | 13.17% | -36.16% | -2180.82% | -160% | -4.26% | - |
| Operating Expenses | 15.41M | 12.88M | 7.08M | 9.24M | 8.08M | 4.47M | 2.32M | 2.05M |
| OpEx % of Revenue | - | 6309.6% | - | - | - | - | - | - |
| Selling, General & Admin | 25.1M | 19.49M | 7.14M | 8.52M | 6.45M | 2.78M | 1.51M | 1.66M |
| SG&A % of Revenue | - | 9546.05% | - | - | - | - | - | - |
| Research & Development | 319.38K | 198.76K | -58.02K | 729.48K | 1.63M | 1.69M | 827K | 388.02K |
| R&D % of Revenue | - | 97.38% | - | - | - | - | - | - |
| Other Operating Expenses | -3M | -6.81M | 0 | -15.18K | 0 | 0 | 0 | 0 |
| Operating Income | -15.84M | -13.29M | -7.86M | -10.13M | -8.74M | -4.5M | -2.33M | -2.06M |
| Operating Margin % | -3990.13% | -6512.09% | - | - | - | - | - | - |
| Operating Income Growth % | - | -69.19% | 22.42% | -15.88% | -94.3% | -92.75% | -13.32% | - |
| EBITDA | -15.81M | -13.16M | -7.08M | -9.24M | -8.08M | -4.47M | -2.32M | -2.05M |
| EBITDA Margin % | -3984.09% | -6447.16% | - | - | - | - | - | - |
| EBITDA Growth % | -115.88% | -85.8% | 23.31% | -14.24% | -80.9% | -92.43% | -13.37% | - |
| D&A (Non-Cash Add-back) | 23.95K | 132.54K | 773.9K | 891.25K | 654.57K | 28.7K | 11.04K | 10.59K |
| EBIT | -272.46M | -269.92M | -7.62M | -9.87M | -3.32M | -4.5M | -2.34M | -2.06M |
| Net Interest Income | 44.89K | -416.66K | -1.66M | 138.12K | -1.32M | -166.75K | 3.33K | 3.6K |
| Interest Income | 165.44K | 0 | 40.3K | 138.12K | 1.32K | 769 | 3.33K | 3.6K |
| Interest Expense | 120.55K | 416.66K | 1.71M | 0 | 1.32M | 167.51K | 0 | 0 |
| Other Income/Expense | -342.67M | -257.04M | -1.47M | 255.01K | 4.1M | -166.75K | -6.87K | 3.6K |
| Pretax Income | -358.5M | -270.34M | -9.33M | -9.87M | -4.64M | -4.66M | -2.34M | -2.06M |
| Pretax Margin % | -90325.9% | -132439.46% | - | - | - | - | - | - |
| Income Tax | 0 | 0 | -30K | -30K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0.32% | 0.3% | 0% | 0% | 0% | 0% |
| Net Income | -370.67M | -282.5M | -9.3M | -9.84M | -4.64M | -4.66M | -2.35M | -2.06M |
| Net Margin % | -93391.33% | -138400.02% | - | - | - | - | - | - |
| Net Income Growth % | -5705.35% | -2938.9% | 5.54% | -112.12% | 0.53% | -98.73% | -14.19% | - |
| Net Income (Continuing) | -358.5M | -270.34M | -9.3M | -9.84M | -4.64M | -4.66M | -2.34M | -2.06M |
| Discontinued Operations | 0 | -12.17M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.11 | -11.16 | -2220.05 | -4983.99 | -3780.28 | -3356.30 | -1683.99 | -1479.06 |
| EPS Growth % | 99.5% | 99.5% | 55.46% | -31.84% | -12.63% | -99.31% | -13.86% | - |
| EPS (Basic) | - | -11.16 | -2220.05 | -4983.99 | -3780.28 | -3356.30 | -1683.99 | -1479.06 |
| Diluted Shares Outstanding | 72.57M | 25.31M | 4.19K | 1.97K | 1.23K | 1.39K | 1.39K | 1.39K |
| Basic Shares Outstanding | 72.57M | 25.31M | 4.19K | 1.97K | 1.23K | 1.39K | 1.39K | 1.39K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Capital exhaustion and scale failure
As reported in recent financial filings, STSS generated a TTM revenue of only $204,120, indicating the firm remains in a precarious pilot phase that lacks the necessary volume to validate its proprietary safety syringe technology within the broader, highly competitive medical device marketplace.
The intermittent nature of revenue recognition suggests that the company has yet to secure consistent, recurring purchase orders from major hospital networks or GPOs. Investors should monitor whether these figures represent genuine end-user adoption or merely initial stocking orders that may not repeat without significant commercial traction.
Based on the company's reported figures, the gross margin of -202.49% highlights a severe inability to absorb fixed manufacturing overhead, suggesting that the current production scale is insufficient to achieve the unit-level profitability required to compete with established industry incumbents like Becton Dickinson.
The negative gross margin implies that every unit sold currently erodes the company's capital base rather than contributing to overhead coverage. This structural imbalance warrants further investigation into whether the current manufacturing process is fundamentally inefficient or if it simply requires a massive increase in throughput to reach a break-even point.
According to the provided income statement data, the extreme volatility in net income, including a net margin of -138400.02%, appears heavily influenced by non-cash charges and potential warrant revaluations rather than core operational performance, complicating the assessment of the firm's true underlying cash burn.
The significant fluctuations in net income across recent quarters suggest that investors should focus on operating cash flow rather than headline earnings to gauge the company's survival runway. The presence of substantial stock-based compensation in certain periods further obscures the true cost of talent acquisition relative to the company's limited revenue generation.
As evidenced by the operating margin of -6512.09%, the company's SG&A and R&D expenditures dwarf its current revenue base, reflecting a cost structure that appears misaligned with the firm's current stage of commercial development and market penetration within the medical instrument sector.
The persistent reliance on high corporate overhead despite minimal revenue suggests that management may be over-investing in infrastructure before establishing a viable product-market fit. This expense discipline, or lack thereof, poses a significant risk to the company's ability to extend its cash runway without resorting to dilutive financing.
Based on the provided financial statements, the most significant risk to the investment thesis is the potential for total capital exhaustion, as the company's massive operating losses relative to its $10.3 million cash balance suggest a limited window to achieve self-sustaining commercial operations.
Short-sellers would likely focus on the lack of a clear path to positive gross margins and the high probability of future equity dilution to fund ongoing operations. The company's inability to scale revenue suggests that the proprietary nature of its technology may not be sufficient to overcome the incumbency advantages held by larger, more diversified medical device manufacturers.
Quick answers to the most common questions about buying STSS stock.
For fiscal year 2025, Sharps Technology, Inc. (STSS) reported total revenue of $0.2M.
Sharps Technology, Inc. (STSS) reported a net loss of $282.5M for the fiscal year ending 2025.
Sharps Technology, Inc. (STSS) reported an operating income of $-13.3M, resulting in an operating profit margin of -6512.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Sharps Technology, Inc. (STSS) generated $-0.4M in gross profit for the year, representing a gross profit margin of -202.5%. This demonstrates the company's core pricing power and production efficiency.